

Sonali M Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7130115/publications.pdf>

Version: 2024-02-01

177
papers

7,816
citations

81434

41
h-index

62345

84
g-index

181
all docs

181
docs citations

181
times ranked

8953
citing authors

#	ARTICLE	IF	CITATIONS
1	Too much and not enough: revisiting maintenance rituximab in indolent lymphomas. <i>Haematologica</i> , 2022, 107, 353-354.	1.7	0
2	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. <i>Haematologica</i> , 2022, 107, 1608-1618.	1.7	16
3	Phase I study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2022, 139, 1147-1159.	0.6	17
4	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	0.6	50
5	Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. <i>Haematologica</i> , 2022, 107, 4-6.	1.7	3
6	Evolution of therapy for limited stage diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 33.	2.8	9
7	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
8	Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. <i>Leukemia and Lymphoma</i> , 2021, 62, 1497-1501.	0.6	1
9	Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma. <i>Npj Genomic Medicine</i> , 2021, 6, 11.	1.7	13
10	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. <i>Journal of Geriatric Oncology</i> , 2021, 12, 585-591.	0.5	10
11	Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. <i>Blood</i> , 2021, 137, 3454-3459.	0.6	4
12	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
13	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV+ lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 3493-3500.	0.6	17
14	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	0.6	7
15	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	1.2	5
16	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 36-44.	0.4	6
17	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	1.7	18
18	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1

#	ARTICLE	IF	CITATIONS
19	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
20	S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements. <i>Blood</i> , 2021, 138, 3565-3565.	0.6	0
21	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL). <i>Blood</i> , 2021, 138, 1349-1349.	0.6	2
22	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3528-3528.	0.6	3
23	Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592). <i>Blood</i> , 2021, 138, 1423-1423.	0.6	2
24	Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608. <i>Blood</i> , 2021, 138, 2425-2425.	0.6	0
25	A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma. <i>Blood</i> , 2021, 138, 2420-2420.	0.6	0
26	Utility Estimation of Rituximab Versus Bendamustine-Rituximab Induction in Indolent Non-Hodgkin Lymphomas Using Patient-Reported Quality of Life Survey Data. <i>Blood</i> , 2021, 138, 4013-4013.	0.6	0
27	Outcomes of Histological Variants of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): A Single-Center Retrospective Study. <i>Blood</i> , 2021, 138, 4548-4548.	0.6	0
28	DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 698-709.	0.3	1
29	Positron Emission Tomographyâ€“Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	0.8	75
30	ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 302-313.	1.8	19
31	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020, 61, 2442-2447.	0.6	1
32	Clinical and Biological Prognostic Factors in Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 647-662.	0.9	3
33	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. <i>Blood</i> , 2020, 136, 27-28.	0.6	9
34	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	0.6	3
35	Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	7
36	Transformed Follicular Lymphoma. , 2020, , 135-163.		0

#	ARTICLE	IF	CITATIONS
37	Reply to E. Hawkes et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 4222-4223.	0.8	0
38	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
39	Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2020, 136, 43-44.	0.6	1
40	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020, 136, 24-26.	0.6	0
41	Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8+ T Cell Population with a Cytotoxic Phenotype. <i>Blood</i> , 2020, 136, 40-41.	0.6	0
42	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020, 136, 4-6.	0.6	0
43	SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	0.6	9
44	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
45	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	0.6	86
46	Phase 1 study of lenalidomide plus dose-adjusted EPOCH in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. <i>Cancer</i> , 2019, 125, 1830-1836.	2.0	16
47	Work-Life Balance Solutions for Physicians—It's All About You, Your Work, and Others. <i>Mayo Clinic Proceedings</i> , 2019, 94, 573-576.	1.4	9
48	PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. <i>Blood</i> , 2019, 133, 2279-2290.	0.6	87
49	Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 356-364.e3.	0.2	88
50	Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sézary syndrome. <i>British Journal of Haematology</i> , 2019, 186, 377-379.	1.2	6
51	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.	0.6	35
52	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
53	Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 2790-2799.	2.5	36
54	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	2.5	18

#	ARTICLE	IF	CITATIONS
55	Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	2.8	11
56	Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. <i>Blood</i> , 2019, 133, 81-93.	0.6	34
57	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.	0.6	13
58	Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas. <i>Blood</i> , 2019, 134, 4031-4031.	0.6	2
59	A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas. <i>Blood</i> , 2019, 134, 351-351.	0.6	5
60	Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL. <i>Blood</i> , 2019, 134, 391-391.	0.6	2
61	A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma. <i>Blood</i> , 2019, 134, 4104-4104.	0.6	0
62	Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes. <i>Blood</i> , 2019, 134, 924-924.	0.6	8
63	Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016. <i>Blood</i> , 2019, 134, 2771-2771.	0.6	0
64	Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. <i>Haematologica</i> , 2018, 103, e151-e153.	1.7	22
65	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
66	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq0 0 0 rBT /Overlock 10 Tt	2.2	20
67	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <i>Cancer</i> , 2018, 124, 1733-1742.	2.0	58
68	Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 91-97.	0.2	4
69	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 700-707.	2.0	16
70	University of Chicago phase II consortium trial of selumetinib (<scp>MEK</scp>i) demonstrates low tolerability and efficacy in relapsed DLBCL. <i>British Journal of Haematology</i> , 2018, 181, 264-267.	1.2	4
71	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 78-85.	2.0	9
72	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	2.0	47

#	ARTICLE	IF	CITATIONS
73	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
74	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.	2.0	20
75	Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	1.2	59
76	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹ I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018, 36, 697-703.	0.8	68
77	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3022.	0.8	102
78	Double hit and double expressors in lymphoma: Definition and treatment. <i>Cancer</i> , 2018, 124, 4622-4632.	2.0	121
79	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 1711-1721.	13.9	796
80	Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. <i>Blood</i> , 2018, 132, 2016-2025.	0.6	93
81	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
82	An update in treating transformed lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 251-261.	0.7	16
83	Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, 7056-7056.	0.8	2
84	Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. <i>Journal of Clinical Oncology</i> , 2018, 36, 7504-7504.	0.8	20
85	The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL). <i>Journal of Clinical Oncology</i> , 2018, 36, 7511-7511.	0.8	6
86	Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL). <i>Journal of Clinical Oncology</i> , 2018, 36, 7549-7549.	0.8	15
87	Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 7568-7568.	0.8	1
88	Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study. <i>Journal of Clinical Oncology</i> , 2018, 36, 7540-7540.	0.8	1
89	<i>Pd-1</i> gene alterations to identify a subset of diffuse large B cell lymphoma that harbor a T cell inflamed phenotype. <i>Journal of Clinical Oncology</i> , 2018, 36, 7566-7566.	0.8	0
90	Characterization of the immunogenomic landscape of follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, e19531-e19531.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 193-200.	0.2	27
92	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28
93	A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. <i>Cancer</i> , 2017, 123, 1174-1183.	2.0	51
94	Treatment of aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2017, 35, 84-87.	0.8	2
95	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	6.9	20
96	Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. <i>Lancet Haematology</i> , 2017, 4, e176-e182.	2.2	77
97	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	1.2	101
98	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 535-546.	1.8	29
99	Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. <i>Blood Advances</i> , 2017, 1, 715-727.	2.5	105
100	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 535-546.	1.8	19
101	Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study. <i>Blood</i> , 2017, 130, 733-733.	0.6	9
102	Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. <i>Journal of Clinical Oncology</i> , 2016, 34, 2997-3004.	0.8	97
103	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. <i>British Journal of Haematology</i> . 2016, 172, 535-544.	1.2	71
104	Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. <i>British Journal of Haematology</i> , 2016, 174, 686-691.	1.2	27
105	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
106	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	3.0	56
107	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016, 128, 2510-2516.	0.6	56
108	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2484-2492.	0.8	106

#	ARTICLE	IF	CITATIONS
109	Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2115.	3.8	6
110	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. <i>Leukemia and Lymphoma</i> , 2016, 57, 2359-2369.	0.6	33
111	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	0.6	246
112	Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3 ⁺ /dimCD4 ⁺ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. <i>Modern Pathology</i> , 2016, 29, 1173-1182.	2.9	36
113	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	0.8	212
114	Phase II Study of Tamsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309. <i>Blood</i> , 2016, 128, 4147-4147.	0.6	2
115	Prospective Phase I Multi-Center Trial Incorporating Lenalidomide (LEN) into Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Patients with Double Hit (DHL) or Double Expressing (DEL) Lymphomas: Final Results. <i>Blood</i> , 2016, 128, 4191-4191.	0.6	5
116	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. <i>Oncotarget</i> , 2016, 7, 4598-4610.	0.8	53
117	Clonal Evolution Pattern of Leukemia Progression and Richter Transformation in Ibrutinib-Relapsed CLL Patients. <i>Blood</i> , 2016, 128, 3961-3961.	0.6	0
118	Impact of Pretransplantation 18F-fluorodeoxy Glucose ⁺ Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
119	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
120	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	0.8	97
121	Highly clonal regulatory T-cell population in follicular lymphoma ⁺ inverse correlation with the diversity of CD8 ⁺ T cells. <i>Oncolmmunology</i> , 2015, 4, e1002728.	2.1	26
122	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
123	Hematopoietic Stem Cell Transplantation in Nodal T Cell Non-Hodgkin Lymphomas: Revisiting the Issues. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 777-779.	2.0	0
124	Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 170, 445-456.	1.2	76
125	Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 373, 1835-1844.	13.9	201
126	New drugs for the treatment of non-Hodgkin lymphomas. <i>Chinese Clinical Oncology</i> , 2015, 4, 14.	0.4	3

#	ARTICLE	IF	CITATIONS
127	Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial. <i>Blood</i> , 2015, 126, 3990-3990.	0.6	0
128	A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 1288-1294.	0.6	7
129	Dietary patterns and the risk of non-Hodgkin lymphoma. <i>Public Health Nutrition</i> , 2014, 17, 1531-1537.	1.1	17
130	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	0.9	16
131	MYC-associated and double-hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches. <i>Cancer</i> , 2014, 120, 3884-3895.	2.0	85
132	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
133	Prognosis in diffuse large B-cell lymphoma. <i>Cancer</i> , 2013, 119, 1129-1131.	2.0	2
134	A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. <i>Cancer</i> , 2013, 119, 1683-1689.	2.0	8
135	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). <i>Leukemia and Lymphoma</i> , 2013, 54, 1405-1410.	0.6	27
136	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2013, 31, 88-94.	0.8	991
137	Dissecting follicular lymphoma: high versus low risk. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 561-567.	0.9	16
138	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3100-3109.	0.8	206
139	Toward a global understanding of lymphoma: epidemiologic clues from the second most populous country. <i>Leukemia and Lymphoma</i> , 2013, 54, 901-902.	0.6	2
140	Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab. <i>Blood</i> , 2013, 122, 247-247.	0.6	6
141	A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial. <i>Blood</i> , 2013, 122, 3044-3044.	0.6	2
142	A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial. <i>Blood</i> , 2013, 122, 371-371.	0.6	8
143	Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intensity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A CIBMTR Analysis. <i>Blood</i> , 2013, 122, 2093-2093.	0.6	10
144	Alternative Donor Transplantation For Adults With Lymphoma: Comparison Of Umbilical Cord Blood Versus 8/8 HLA-Matched Donor (URD) Versus 7/8 URD. <i>Blood</i> , 2013, 122, 161-161.	0.6	6

#	ARTICLE	IF	CITATIONS
145	The Influence Of Lifestyle Factors On Tumor-Related Markers and The Microenvironment In Follicular Lymphoma (FL): Novel Interactions and Collective Impact On Survival. <i>Blood</i> , 2013, 122, 1762-1762.	0.6	0
146	Single Agent Ofatumumab In Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results From a Phase II Open Label Study. <i>Blood</i> , 2013, 122, 5131-5131.	0.6	0
147	Targeting mTOR in mantle cell lymphoma: Current and future directions. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 175-183.	0.7	25
148	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1255-1264.	2.0	27
149	Maintenance rituximab revisited: is it worth the cost?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2331-2332.	0.6	0
150	What Is the Best Strategy for Incorporating New Agents into the Current Treatment of Follicular Lymphoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 481-487.	1.8	0
151	Personalized Treatment of Lymphoma: Promise and Reality. <i>Seminars in Oncology</i> , 2011, 38, 225-235.	0.8	10
152	Old versus frail: why it matters in lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 938-940.	0.6	2
153	Temsirolimus Has Activity in Non-“Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2010, 28, 4740-4746.	0.8	181
154	The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 317-323.	0.6	57
155	The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study. <i>Blood</i> , 2010, 116, 964-964.	0.6	22
156	Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival. <i>Blood</i> , 2010, 116, 3124-3124.	0.6	2
157	Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.. <i>Blood</i> , 2009, 114, 933-933.	0.6	9
158	Management of relapsed diffuse large B-cell lymphoma. <i>Current Oncology Reports</i> , 2008, 10, 393-403.	1.8	10
159	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. <i>British Journal of Haematology</i> , 2008, 140, 313-319.	1.2	26
160	Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 904-912.	2.0	56
161	Anti-Bcl2 therapy in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1232-1233.	0.6	5
162	CHOP plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term Benefits: A Case Report and Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2007, 38, 19-23.	0.6	2

#	ARTICLE	IF	CITATIONS
163	CHOP Plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term benefits: A Case Report and Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2007, 38, 59-62.	0.6	5
164	Reduced-intensity transplantation for lymphoma. <i>Current Treatment Options in Oncology</i> , 2006, 7, 295-305.	1.3	3
165	Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906. <i>Leukemia and Lymphoma</i> , 2006, 47, 1511-1517.	0.6	9
166	Molecular Inhibition of mTOR with Temsirolimus (TORISELâ„¢, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.. <i>Blood</i> , 2006, 108, 2483-2483.	0.6	3
167	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2006, 108, 3675-3675.	0.6	0
168	Something old, something new. <i>Leukemia and Lymphoma</i> , 2006, 47, 576-7.	0.6	0
169	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. <i>Blood</i> , 2005, 106, 2022-2022.	0.6	1
170	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. <i>Blood</i> , 2004, 103, 4373-4374.	0.6	6
171	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST).. <i>Blood</i> , 2004, 104, 1145-1145.	0.6	11
172	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. <i>Blood</i> , 2004, 104, 2321-2321.	0.6	1
173	Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.. <i>Blood</i> , 2004, 104, 2500-2500.	0.6	1
174	Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.. <i>Blood</i> , 2004, 104, 918-918.	0.6	2
175	Nonmyeloablative transplantation for lymphoma. <i>Current Treatment Options in Oncology</i> , 2003, 4, 261-268.	1.3	2
176	Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 291-302.	1.1	7
177	Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. <i>Blood</i> , 2003, 102, 43-52.	0.6	630